Encainide

Summary

Encainide (CHEMBL315838) is an approved small-molecule anti-arrhythmia drug (ATC C01BC08); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01BC08
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 352.5 Da · C22H28N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL315838
Name	Encainide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	48041
ChEBI	CHEBI:4788
ATC	C01BC08
Molecular formula	C22H28N2O2
Molecular weight	352.5
InChIKey	PJWPNDMDCLXCOM-UHFFFAOYSA-N

SMILES: CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC

IUPAC name: 4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide

ChEBI definition: 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.

Pharmacological roles (ChEBI): anti-arrhythmia drug, sodium channel blocker.

Also known as: Encainida, Encainide, encainide, ENCAINIDE

Parent form; salt/anhydrous children: CHEMBL2106155

Patent coverage: 993 distinct patent families (3,255 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Histamine H2 receptor, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2A	6.99	AC50	103.2	nM	CHEMBL_ACT_25173844
HTR2C	6.09	AC50	810	nM	CHEMBL_ACT_25132481
HTR2A	5.66	AC50	2200	nM	CHEMBL_ACT_25225818
KCNH2	5.62	AC50	2416	nM	CHEMBL_ACT_25118870
OPRK1	5.44	AC50	3604	nM	CHEMBL_ACT_25130066
HTR2B	5.44	AC50	3662	nM	CHEMBL_ACT_25164285

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000526	PHASE3	COMPLETED	Cardiac Arrhythmia Suppression Trial (CAST)
NCT00000504	PHASE2	COMPLETED	Cardiac Arrhythmia Pilot Study (CAPS)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).